Elitek Efficacy, Onset Of Action Are Advantages Over Allopurinol, Sanofi Says
This article was originally published in Pharmaceutical Approvals Monthly
Sanofi-Synthelabo is highlighting the efficacy and onset of action of its uricolytic agent Elitek (rasburicase) compared to allopurinol, the standard treatment for hyperuricemia.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class